<DOC>
	<DOC>NCT02469155</DOC>
	<brief_summary>The study will evaluate the antipsychotic efficacy of ITI-007 in a randomized, double-blind, parallel-group, placebo- and active-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.</brief_summary>
	<brief_title>A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>male or female subjects of any race, ages 1860 inclusive, with a clinical diagnosis of schizophrenia experiencing an acute exacerbation of psychosis any subject unable to provide informed consent any female subject who is pregnant or breastfeeding any subject judged to be medically inappropriate for study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>